SIRPA and neoplasm: Engineered oncolytic herpes simplex virus encoding CD47 targeting antibodies have been used to disrupt the CD47-SIRPα signaling axis and enhance both macrophage-mediated ADCP and NK cell-mediated ADCC, harnessing the overexpression of the CD47 “don’t eat me” signal on many tumor cells [45, 46].